Introduction
In Australia and New Zealand, 7208 people have sought Voluntary Assisted Dying (VAD), with cancer being the most prevalent primary diagnosis amongst these patients. Despite its increasing relevance, VAD remains a new practice area for many Australian clinicians, including those in oncology. Given the intersection of VAD and cancer, it is beneficial for oncology professionals to understand the role of all VAD clinicians (including pharmacists) in a patient’s end-of-life journey.
In Queensland, pharmacists with the Queensland Voluntary Assisted Dying Support and Pharmacy Service (QVAD SPS) are responsible for dispensing VAD substances and educating eligible patients, their families, and clinicians on the management and administration of these substances. These pharmacists play a pivotal role in end-of-life care, often working closely with the broader healthcare team to provide holistic, patient-centred care. To effectively offer these services, pharmacists need extensive knowledge and training in all aspects of end-of-life care.
Objective
This presentation will examine the unique role of QVAD SPS pharmacists, focusing on their specialized skills and expertise that enable them to support eligible VAD patients at end of life.
Key Findings/Description
QVAD SPS pharmacists undergo extensive training upon onboarding, which includes VAD legislation and processes in Queensland, pharmacology of VAD substances, substance management, referral pathways for end-of-life services, practical aspects of death, end-of-life communication, and bereavement care. They are trained to offer standardised VAD substance counselling that is compassionate, tailored to the individual, and also covers their legislative and professional obligations. Furthermore, QVAD SPS provides opportunities for pharmacists to debrief, reflect, and enhance their practice through supervision.
Conclusion
QVAD SPS pharmacists are well-supported and trained to provide high-quality VAD services in Queensland. Their role is crucial in collaborating with the wider healthcare team to ensure that patients, their families, and clinicians receive comprehensive support with VAD substance supply and administration.